A Phase I Study of SNH-119014 in Healthy Volunteers

  • STATUS
    Recruiting
  • End date
    Mar 28, 2026
  • participants needed
    96
  • sponsor
    ScinnoHub Pharmaceutical Co., Ltd.
Send
Updated on 5 August 2025
See if I qualify
Accepts healthy volunteers

Summary

SNH-119014 is an oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR) being developed for the treatment of hemolytic anemias. This initial study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of SNH-119014 in the context of Phase 1 studies in healthy volunteers. The effects of food on the absorption of SNH-119014 will also be evaluated in healthy volunteers.

Details
Condition Hemoglobinopathy
Age 18years - 45years
Clinical Study IdentifierNCT07087262
SponsorScinnoHub Pharmaceutical Co., Ltd.
Last Modified on5 August 2025

Eligibility

 Yes No Not Sure

Inclusion Criteria

Healthy male or female subjects
-45 years of age, inclusive
Male subjects with body weight ≥50 kg, female subjects with body weight ≥45 kg; BMI ≥18.5 and ≤28.0 kg/m2
Must provide written informed consent

Exclusion Criteria

History of or current clinically significant circulatory system, endocrine system, nervous system, digestive system, respiratory system, urinary system, ophthalmology, hematology, immunology, psychiatry disorder, as judged by the investigator；
Subjects who have undergone major surgery 6 months prior to screening or who plan to undergo surgery during the study period
Clinically significant abnormal physical examination, vital signs, chest X-ray, laboratory tests during the screening period as judged by the investigator
Subjects with QTcF>450 ms, or with other ECG clinically significant abnormalities during the screening period as judged by the investigator
Subject has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), treponema pallidum antibody, or human immunodeficiency virus (HIV) antibody at screening
Subjects who have a known chronic liver disease, or who have clinically significant abnormal liver function test results during the screening period
History of urinary system diseases
History of dysphagia or any gastrointestinal disorder affecting drug absorption
History of malignancy
History of severe allergies or allergic to the study drug or any of its components. Serious adverse reaction or hypersensitivity to any drug or the formulation excipients
Failure to follow a consistent diet
Over 5 cups (200 ml per cup) of tea, coffee, or caffeinated beverages were consumed daily during the 3 months prior to screening
Consumption of a specific diet (e.g. grapefruit and grapefruit-containing products, chocolate, any food containing caffeine), or vigorous exercise, or other factors affecting drug absorption, distribution, metabolism, excretion within 48 hours before the dose of study drug
Subjects who have taken any drugs that alter the activity of liver enzymes and/or transporters within 28 days prior to screening
Females who are pregnant or lactating and subjects who are unable to use one or more nonpharmacological contraceptives
Subjects who have taken any prescribed or over-the-counter drug or herbal remedies or nutraceutical product within 14 days before the dose of study drug
Subjects who smoked more than 5 cigarettes per day during the 3 months prior to screening, or who cannot accept a smoking ban throughout the study
Alcohol intake >14 units per week within 6 months prior to screening (1 unit is equal to 14g of alcohol such as 360mL of beer, 45mL of 40% spirit, 150mL of wine, or a confirmed positive alcohol breath test, or alcohol prohibition is not acceptable throughout the study
History of drug abuse in the past 1 year prior to screening, or a confirmed positive drugs of abuse test result before randomization
Subjects who plan to conceive or donate sperm or eggs during the study or within 3 months after completion of study
Subjects has received study drug in another clinical study within 3 months before the dose of study drug
Subjects who have donated blood or loss ≥400 mL of blood within 3 months before the dose of study drug, or who plan to donate blood or blood components during the study or within 3 months after completion of study
Subjects who have received a live attenuated vaccine within 28 days before the dose of study drug
Subjects who cannot tolerate venipuncture, or those with a history of needle fainting or blood fainting
In the opinion of the investigator, the subject is not suitable for entry into the study
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Accepts healthy volunteers

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.